Brain Cancer

Biden’s 2020 vision: ‘Trump is going to be 74, and I’ll be 77’ Stephen Colbert: ‘That’s the sound of a door creaking open’It’s Day 3 of Biden watch, and the vice president still is not definitively shutting down talk of a run for the presidency in 2020.

Easygoing Joe Biden remains loose about 2020 White House bid ‘I’m not committing not to run’ for president, Biden saysVice President Joe Biden said Monday he may run for president in 2020. Or at least he said he wouldn’t not run.

Why smart people make bad decisions about investing The smarter and more creative we are, the more elaborate stories we can tell ourselves to justify our poor decisionsThe smarter and more creative we are, the more elaborate stories we can tell ourselves to justify our poor decisions.

More patient deaths in Juno clinical trial casts clouds over cancer drug’s future Too early to know future of halted trial, company says Two patient deaths this week come on the heels of deaths this summer.

UPDATE: Juno Therapeutics plummets 30% in pre-market trade after two patient deathsJuno Therapeutics Inc. shares plummeted 30.4% in pre-market trade Wednesday after the company said two patients in its cancer trial had died. Both patients experienced brain trauma earlier in the week during a phase 2 trial for a leukemia treatment, the company said. Two patients also died in early July in , but the company was allowed to resume the trial without the chemotherapy drug fludarabine, which Juno caused the deaths in combination with the company's JCAR015 drug. This week, Juno put the trial on clinical hold, and said it is working with the Food and Drug Administration and the Data and Safety Monitoring Board, an independent expert advisory group, to "determine next steps." The company said its other product candidates targeting the B Cell Specific Antigen CD19 won't be affected. Juno shares have dropped 32.0% year-to-date, compared with a 7.8% rise in the S&P 500 .

The case against legalizing marijuana Big business and politicians create a smokescreen around marijuana’s health hazardsBusiness people who want to sell marijuana and politicians who want to tax it mislead voters about pot’s health consequences, writes Brett Arends.

Biotech stocks have plenty of catalysts around the corner While buyouts are looming, political bashing of drug prices has died down While buyouts are looming, political bashing of drug prices has died down, says Michael Brush.

Six new medical technologies worth watching Among them: advances in surgical robots and early cancer screeningFrom growing blood vessels in labs to applying advanced nanotechnology to cancer testing, here are some emerging technologies that could have a big impact on medicine in coming years.

IBM’s Watson will now help spot breast cancer and other diseases Watson partners with medical centers to predict and treat disease IBM’s Watson will use big-data technologies to improve personalized care and treat disease.

Biotech stocks are in for more election trouble on drug pricing Hillary Clinton and Donald Trump have vowed to take actionHillary Clinton and Donald Trump have vowed to take action, writes Michael Brush.

Should cellphones have warning labels? Supporters of warnings say consumers should be alerted to possible risks. Opponents say the risk, if any, is not great enough to warrant itWe press them against our ears every day, often for hours. We carry them around with us in our pockets, front, rear and breast.

Link between cell phones and cancer is real, according to major government study Study finds low incidences in ratsA major U.S. government study on rats finds a link between cellphones and cancer, an explosive finding in the long-running debate about whether mobile phones cause health effects.

The staggering cost of breast cancer Medical bills can rack up to $100,000, depending on coverage and treatmentYou’d be hard-pressed to find a woman whose life is untouched by breast cancer. Roughly one in eight American women is expected to develop invasive breast cancer in her lifetime.

S&P 500, Dow extend gains to fifth day Russell 2,000 jumps 0.9%, outperforming S&P 500 U.S. stocks eke out small gains on Monday while the S&P 500 and Dow industrials extend their winning streak to five straight sessions, in part thanks to a jump in oil prices.

Celldex Therapeutics' stock plunges on heavy volume after brain cancer trial disappointedCelldex Therapeutics Inc.'s stock plunged 51% in active premarket trade Monday, after an independent panel recommended that the company discontinue the late-stage trial of its brain cancer treatment following disappointing trial results. Volume was already over 760,000 shares about 75 minutes before the open, to make it the fourth-most active stock in the premarket session. An independent data safety and monitoring board has determined that the Phase 3 study of Rintega will not reach its primary endpoint statistical significance for overall survival. Celldex said it would discontinue the study. "We are extremely disappointed for patients that the ACT IV study was not successful," said Chief Executive Anthony Marucci. "While this is certainly not the desired outcome, we remain steadfast believers in the power of immunotherapy to transform the future of cancer treatment." The stock had tumbled 48% year to date through Friday, and 72% over the last year, while the S&P 500 has slipped 4.8% in the year.

Raiders quarterback Stabler had traumatic brain condition, New York Times reportsSignal caller Ken “The Snake” Stabler, admitted posthumously to the Hall of Fame as a senior candidate over the weekend, had a history of severe concussions.

The simple reason President Obama can’t cure cancer State of the Union goal is a utopian ‘magic bullet,’ cancer experts saidLaunching a new cancer fighting initiative was a key part of President Barack Obama’s State of the Union speech. But many cancer experts agree say a cure isn’t possible.

Porn may become a public-health problem in Utah Activist calls porn “one of the biggest unregulated social experiments that’s ever occurred”A new proposal in Utah has reinvigorated the debate about whether porn is a public health problem.

Here’s a reason to ignore this plunging market — it knows nothing Critical information ahead of the U.S. market’s openWednesday could deliver another brutal blow to the bulls. Our call of the day says don’t get too rattled by your screens because this market doesn’t know it all.

10 biotech stocks to buy at ‘silly’ cheap prices The industry is healthier than ever, and three main concerns don’t pan outThe industry is healthier than ever, and three main concerns don’t pan out, writes Michael Brush.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. All quotes are in local exchange time. Real time last sale data provided by NASDAQ. More information on NASDAQ traded symbols and their current financial status. Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. S&P/Dow Jones Indices (SM) from Dow Jones & Company, Inc. SEHK intraday data is provided by SIX Financial Information and is at least 60-minutes delayed. All quotes are in local exchange time.